Fink Family Office

Thank you everyone who came to the Fink Family Office Drinks last night. As always it was an amazing event, with amazing people who are changing the world! Cant believe we managed to get Co Investor Andy Serkis along as well! Thank you to the VC's attending Johnathan Matlock from Empirical Ventures Kevin Chong and Devin Kohli from Outward VC Heligan Group Beverley Gower-Jones OBE FEI from Clean Growth Fund Hugh Bowen from SOSV Tom Davies from Development Bank of Wales Anoushka Patel from MMC Ventures Amrit Sami from Mercia Ventures Alexandra Lindsay from Maven Capital Partners Thank you to All our amazing Port Co's Harry Samuel at Affordable Housing & Healthcare Group Anthony Parker and Michael Khan ARGONAUTE RNA LIMITED Ali Celiker and the team BPX Digital Securities Exchange Shachar Bialick and Curve Asel Sartbaeva at EnsiliTech Stephen Avila at Etopia Gregg Kantor at flyp Glyn Edwards MitoRx Therapeutics Stephen Wilks and Lukas Feddern Novabook John Terry Neuronostics And anyone else I have missed out!

1st Exit of the year - congratulations Pupil

Empirical Ventures is proud to highlight MintNeuro, one of our portfolio companies revolutionising neural implants with cutting-edge semiconductor technology has secured three prestigious Advanced Research + Invention Agency (ARIA) grants to develop next-generation tools for precision brain circuit modulation, paving the way for transformative treatments for neurological and neuropsychiatric disorders. - Precision 4D Control of Cortical Circuit Function - Brain Mesh: A Distributed Neural Interface - Minimally Invasive Temporal Interference Stimulation With Advanced Research + Invention Agency (ARIA)'s £69M programme backing breakthroughs in neurotechnology, MintNeuro is tackling challenges like Alzheimer’s, epilepsy, and depression—conditions impacting 1 in 6 people in the UK, costing the NHS £4.4 billion annually. Their innovations aim to provide precise, minimally invasive solutions where existing technologies fall short. At Empirical Ventures, we invest in pioneering ventures like MintNeuro that address significant global challenges. Our second SEIS/EIS Fund is now open for pre-registration, offering investors the chance to support the next wave of deep-tech innovation. Register your interest today: Empirical Ventures Fund 2 – https://lnkd.in/eJtJS-V7 Capital at risk. For professional investors only. #SEIS #EIS #VentureCapital #DeepTech #Innovation #EarlyStageInvesting

Curve Appoints Lord Stanley Fink as Chair of Board “Lord Fink is a finance virtuoso, who has been instrumental to Curve’s success as a shareholder, and we are honoured to welcome him to our Board as incoming Chair. With exceptional experience in banking alongside his proven capabilities in scaling highly successful businesses, Lord Fink is an asset due to his expertise as a deft financial operator as well as his authority in the industry. With fintechs now operating shoulder-to-shoulder with global tech giants, we see an unprecedented opportunity to deepen consumer-focused innovation. The arrival of Lord Fink epitomises our commitment to continued advancement, user-inspired invention, and industry leadership,” said Shachar Bialick, Founder & CEO of Curve. https://lnkd.in/ewAeGWeh Gavin Horwich Eric Molitor Francis Darby Darren Hackett David Harper CPA, CA (ACA equivalent) Edoardo Volta Andrea Della Corte #fintech #finance #banking #paytech #payments #fintechnews #paymentsnews

Empirical Ventures Year in Review; The vision for Empirical Ventures is to build the premiere DeepTech investor across the UK and Europe. Bringing together a team of PhD scientists with deep domain knowledge as operators, entrepreneurs and investors to build a venture capital fund that is truly differentiated. Last week we brought together LPs, Angel Investors, Portfolio Companies and Stakeholders to celebrate 2024 - kindly hosted at a unique venue by the Fink Family Office and joined by Shadow Secretary of State for Science, Innovation and Technology Alan Mak MP. What a year it has been at Empirical Ventures. With the launch of our first Fund we brought our total AUM to £14m. In 2024 we invested in 9 pre-seed and seed stage DeepTech rounds (Xgenera, Exciting Instruments, MintNeuro, Silveray, Signapse, Neuronostics, Transdermal Diagnostics Ltd, ARGONAUTE RNA LIMITED, MitoRx Therapeutics) tackling everything from semiconductors for neural implants to digital x-ray films to bispecific gene silencing therapies. These companies joined existing portfolio companies (Halo Therapeutics, WASE, OSSTEC, Albotherm, EnsiliTech, CheMastery Group Ltd, Muddy Machines, Zentraxa , QV Bioelectronics) taking the total portfolio to 18. We welcomed two new team members taking the team to 6 people: our two founders Dr Ben Miles, Ph.D. and Johnathan Matlock, supported by Curran Kalha, Ph.D., Claudia Fryer, Trang K. Nguyen and Madeleine Nichols, PhD. We also welcomed three venture partners Alexander Fink, Keith Lipman and Steve Chasan A unique feature of DeepTech is that things take time to develop. Our LPs recognise this requirement to remain patient in the early years of the scientific commercialisation journey. So in this first 2-3 year period we are often looking for signals of positive momentum, 2024 has been tremendously exciting for our portfolio and we believe a number of companies are poised for significant growth in 2025. Finally a big shout out to our investors. Investors that share our vision for backing the best entrepreneurial scientists as they change the very fabric of the world in which we live. A specific shout out to British Business Investments (Mark Barry and Luke W.) and the Regional Angels Co-investment Fund which has been instrumental in increasing the firepower we can deploy into these businesses. In the year that we launched our first fund a special shout out goes to the stakeholders who supported us along the way, a special thanks to the following; SFC Capital Partner (Marguerite Crossfield and Stephen Page) - AIFM RW Blears (Ollie Blears, Lannie Churchill, Bethany Johnson) - Fund Structuring Abel + Imray (Tom Turner) - IP We have big plans for 2025, so please like, follow and support EV as we continue to back scientists who turn theory into action. CAPITAL AT RISK. FOR PROFESSIONAL INVESTORS ONLY.

Well done to top scout Jordan Fink at the Fink Family Office for making this come together! Excited to be part of the Exciting Instruments family!

What does the future of measuring biological interactions look like and how can it be scaled for high-throughput discovery? Exciting Instruments might just have the answer. Today they announce their £4m investment round to commercialise their EI-Flex instrumentation. A The University of Sheffield spinout Empirical Ventures is excited to have led on technical due diligence and participated in this investment round alongside lead Northern Gritstone, Praetura Ventures, Meltwind Advisory LLP (Jonathan Milner) and Stan Boland. Having already built and sold instruments into academia Tim Craggs and Robert Bell begin the next phase of their journey. They specialise in developing single-molecule fluorescence resonance energy transfer (smFRET) instrumentation, particularly their EI-FLEX device, which addresses limitations in single-molecule spectroscopy. The EI-FLEX device is compact, user-friendly, and designed to be used outside of dark rooms, which traditional instruments require. It also includes a vibration-suppressing base, making it accessible for non-expert users. Their next commercial device will integrate a plate reader and auto-focuser for high-throughput screening, enhancing its utility in drug development. Their adaptable consumables and modular design provide flexibility to evolve with industry needs, particularly in pharma. Positioning the company to penetrate three major markets: direct academic sales, drug development, and clinical diagnostics. Each market offers substantial growth potential. Thank you to all the parties involved in this deal including our partners Abel + Imray (Tom Turner). A shout out to Jessica McCreadie, Alison Maughan from Northern Gritstone and Vicky Protano and Nina Latham from Mills & Reeve. Internally Curran Kalha, Ph.D. Dr Ben Miles, Ph.D., Trang K. Nguyen, Madeleine Nichols, PhD, Thank you to Alexander Fink, Keith Lipman and Mark Stevenson who supported from our LP network. Thanks to Jordan Fink who made the introduction to Tim and Robert. CAPITAL AT RISK. FOR PROFESSIONAL INVESTORS ONLY https://lnkd.in/eWFUXQbJ

Happy International womens day to all the amazing women in the world and our amazing female founders Asel Sartbaeva Merlie Calvert 🐸 Vivi Friedgut 🚀 Anna Andreou